A Randomized, Double-blind Phase III Clinical Trial to Evaluate the Lot-to-lot Consistency of Three Consecutive Batches of Recombinant Herpes Zoster Vaccine (CHO Cell) Produced At a Commercial Scale in Subjects Aged 40 Years and Older.

The article discusses a randomized, double-blind Phase III clinical trial evaluating the lot-to-lot consistency of three consecutive batches of recombinant herpes zoster vaccine (CHO cell) in subjects aged 40 years and older. The trial aims to assess the consistency of the vaccine's production lots and their impact on subjects after receiving two doses on a 0, 2-month schedule. The study involves 1200 subjects and focuses on measuring anti-gE antibody levels and monitoring adverse events following vaccination. The trial is set to be completed by May 1, 2025, and is being conducted in China. [Extracted from the article]